Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

Michael Sun,Justin M Lebenthal,Jones T. Nauseef,Muhammad Junaid Niaz,Sabrina Guervil,Escarleth Fernandez,Amie Patel,Angela Tan,Panagiotis J. Vlachostergios,Joseph R. Osborne,Ana M. Molina,Cora N. Sternberg,David M. Nanus,Neil H. Bander,Scott T. Tagawa

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

2021

Michael Sun
Justin M Lebenthal
Jones T. Nauseef
Muhammad Junaid Niaz
Sabrina Guervil
Escarleth Fernandez
Amie Patel
Angela Tan
Panagiotis J. Vlachostergios
Joseph R. Osborne
Ana M. Molina
Cora N. Sternberg
David M. Nanus
Neil H. Bander
Scott T. Tagawa

158Background: CTC counts are an independent prognostic factor in men with mCRPC; certain changes following treatment (conversion from detectable to undetectable or unfavorable to favorable) are as...

Keywords:

post treatment
Cancer research
Prostate cancer
Glutamate carboxypeptidase II
castration resistant
Circulating tumor cell
Medicine
Targeted radionuclide therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations